Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for vitiligo: experimental drug aims to restore skin color

NCT ID NCT06113328

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tested an experimental drug called MK-6194 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the drug could safely reduce the amount of vitiligo on the face compared to a placebo. The trial was stopped early, but the results help researchers understand how to treat this skin condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

169 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has a clinical diagnosis of non-segmental vitiligo * Has non-segmental vitiligo with disease duration of at least 6 months * Has depigmentation contributing to Facial Vitiligo Area Scoring Index (F-VASI) ≥ 0.3 at screening and baseline * Has depigmented facial body surface area (BSA) ≥0.3% at screening and baseline * Has Total Vitiligo Area Scoring Index (T-VASI) ≥4 at screening and baseline * Has total body vitiligo area ≥4% at screening and baseline excluding hands and feet involvement Exclusion Criteria: * Has segmental vitiligo * Has ≥50% leukotrichia on face or body * Has any other dermatological diseases that would interfere with vitiligo assessments * Has history of or current inflammatory condition other than vitiligo that, in the opinion of the investigator, could interfere with the evaluation of vitiligo * Has a known systemic hypersensitivity to interleukin 2 (IL-2), or modified IL-2 including MK-6194, or its inactive ingredients * Has an active or clinically significant infection requiring hospitalization or treatment with IV anti-infectives within 4 weeks prior to Randomization, or oral/intramuscular anti-infective therapy within 2 weeks prior to Randomization * Has symptomatic heart failure (New York Heart Association class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening * Has a severe chronic pulmonary disease requiring oxygen therapy * Has a transplanted organ, which requires continued immunosuppression * Has a history of any malignancy, except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix * Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB * Has confirmed or suspected COVID-19 infection * Has history of drug or alcohol abuse within 6 months prior to Screening * Has had major surgery within 3 months prior to Screening OR has a major surgery planned during the study * Has had an inadequate response (as evaluated by a dermatologist or local physician specialist equivalent) to previous treatment with a Janus kinase inhibitor (JAKi) after an appropriate treatment duration (eg, ≥12 weeks) * Has received prohibited medications within protocol-specified timeframes prior to Randomization * Has participated in another investigational clinical study within 4 weeks prior to Randomization * Has donated or lost ≥1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit * Has received cosmetic or other procedures that could interfere with evaluation of vitiligo during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-segmental vitiligo

Contacts and locations

Locations

  • Amsterdam UMC, locatie AMC-Dermatology ( Site 1101)

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Ankara Bilkent Şehir Hastanesi-Dermatology ( Site 1502)

    Ankara, 06800, Turkey (Türkiye)

  • Burke Pharmaceutical Research ( Site 0124)

    Hot Springs, Arkansas, 71913, United States

  • CHU de Bordeaux Hop St ANDRE ( Site 0804)

    Bordeaux, Aquitaine, 33075, France

  • Cahaba Dermatology & Skin Health Center ( Site 0127)

    Birmingham, Alabama, 35244, United States

  • Cantonal Hospital St.Gallen ( Site 1402)

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0803)

    Nice, Alpes-Maritimes, 06202, France

  • Centre de Recherche Dermatologique du Quebec metropolitain ( Site 0002)

    Québec, Quebec, G1V 4X7, Canada

  • Centro Integral de Reumatología del Caribe ( Site 0405)

    Barranquilla, Atlántico, 080002, Colombia

  • Centro Internacional de Estudios Clinicos (CIEC) ( Site 0302)

    Santiago, Region M. de Santiago, 8420383, Chile

  • Centro de Atención e Investigación Clínica ( Site 0507)

    Aguascalientes, 20129, Mexico

  • Centro de Investigaciones Metabólicas (CINME)-Dermatology ( Site 0203)

    Buenos Aires, Buenos Aires F.D., C1027AAP, Argentina

  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0901)

    Berlin, 10117, Germany

  • CliniSalud ( Site 0401)

    Envigado, Antioquia, 055422, Colombia

  • Clinica Dermacross ( Site 0301)

    Santiago, Region M. de Santiago, 7640881, Chile

  • Clinica Universidad de Navarra ( Site 1305)

    Madrid, Madrid, Comunidad de, 28027, Spain

  • Clinical Research Chile SpA ( Site 0304)

    Valdivia, Los Ríos Region, 5110683, Chile

  • Cryptex Investigación Clínica S.A. de C.V. ( Site 0515)

    Cuauhtémoc, Ciudad de México, Mexico City, 06100, Mexico

  • Dawes Fretzin Clinical Research Group, LLC ( Site 0106)

    Indianapolis, Indiana, 46250, United States

  • Dermatology Specialists of Spokane ( Site 0126)

    Spokane, Washington, 99202, United States

  • Dermisur ( Site 0305)

    Osorno, Los Lagos Region, 5310644, Chile

  • Diex Recherche Quebec Inc. ( Site 0008)

    Québec, Quebec, G1V 4T3, Canada

  • Diex Recherche sherbrooke Inc. ( Site 0007)

    Sherbrooke, Quebec, J1L 0H8, Canada

  • Enverus Medical Research ( Site 0006)

    Surrey, British Columbia, V3V 0C6, Canada

  • Erciyes Universitesi Tıp Fakultesi Hastaneleri-Dermatology and Venereology ( Site 1506)

    Kayseri, 38039, Turkey (Türkiye)

  • Fundación Valle del Lili ( Site 0412)

    Cali, Valle del Cauca Department, 760032, Colombia

  • HENRI MONDOR HOSPITAL ( Site 0801)

    Créteil, Val-de-Marne, 94000, France

  • Hacettepe Universite Hastaneleri-Dermatology ( Site 1501)

    Altindağ, Ankara, 06230, Turkey (Türkiye)

  • Hamzavi Dermatology - Canton ( Site 0101)

    Canton, Michigan, 48187, United States

  • Healthy Medical Center S.A.S ( Site 0403)

    Zipaquirá, Cundinamarca, 250252, Colombia

  • Hospital Aleman-Dermatologia ( Site 0209)

    Buenos Aires, C1118AAT, Argentina

  • Hospital Universitari de Bellvitge-Dermatology ( Site 1307)

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Hospital Universitario Puerta del Mar ( Site 1302)

    Cadiz, Andalusia, 11009, Spain

  • Hôpital Edouard Herriot ( Site 0802)

    Lyon, Auvergne-Rhône-Alpes, 69003, France

  • IPS SURA San Diego ( Site 0408)

    Medellín, Antioquia, 50016, Colombia

  • Indiana University Health University Hospital-Indiana University School of Medicine, Department of (

    Indianapolis, Indiana, 46202, United States

  • Inha University Hospital ( Site 1992)

    Incheon, 22332, South Korea

  • Instituto Medico Strusberg ( Site 0208)

    Córdoba, Córdoba Province, X5000EDC, Argentina

  • International Clinical Research - Tennessee LLC ( Site 0120)

    Murfreesboro, Tennessee, 37130, United States

  • Medical University of South Carolina-Dermatology Research ( Site 0114)

    Charleston, South Carolina, 29425, United States

  • Metro Boston Clinical Partners ( Site 0110)

    Brighton, Massachusetts, 02135, United States

  • Nagoya City University Hospital-Dermatology ( Site 2002)

    Nagoya, Aichi-ken, 467-8602, Japan

  • New Cross Hospital ( Site 1601)

    Wolverhampton, WV10 0QP, United Kingdom

  • Osaka University Hospital ( Site 2004)

    Suita, Osaka, 565-0871, Japan

  • Paratus Clinical Research Woden ( Site 1703)

    Phillip, Australian Capital Territory, 2606, Australia

  • Pontificia Universidad Catolica de Chile-CICUC ( Site 0308)

    Santiago, Region M. de Santiago, 8330034, Chile

  • Progressive Clinical Research ( Site 0108)

    San Antonio, Texas, 78213, United States

  • Psoriahue ( Site 0205)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425DKG, Argentina

  • Queen Elizabeth Hospital Birmingham ( Site 1603)

    Birmingham, Warwickshire, B15 2TH, United Kingdom

  • Rambam Health Care Campus-Dermatology ( Site 1002)

    Haifa, 3109601, Israel

  • Remington Davis Clinical Research-Outpatient ( Site 0104)

    Columbus, Ohio, 43215, United States

  • Royal London Hospital-Dermatology Research Unit ( Site 1605)

    London, England, E1 1BB, United Kingdom

  • Seoul National University Hospital-Dermatology ( Site 1991)

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System-Department of Dermatology ( Site 1993)

    Seoul, 03722, South Korea

  • Sheba Medical Center-Dermatology ( Site 1001)

    Ramat Gan, 5265601, Israel

  • Sinclair Dermatology ( Site 1704)

    Melbourne, Victoria, 3002, Australia

  • Skin Health Institute Inc.-Trials ( Site 1702)

    Carlton, Victoria, 3053, Australia

  • Stat Research S.A. ( Site 0204)

    Buenos Aires, Buenos Aires F.D., C1023AAB, Argentina

  • The Vitiligo & Pigmentation Institute of Southern California ( Site 0115)

    Los Angeles, California, 90036, United States

  • Tokyo Medical University Hospital ( Site 2001)

    Shinjuku-ku, Tokyo, 160-0023, Japan

  • UZ Gent ( Site 0604)

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • UZ Leuven ( Site 0601)

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Unidad biomedica avanzada monterrey-Clinical Trials ( Site 0504)

    Monterrey, Nuevo León, 64460, Mexico

  • Universitaetsklinikum Erlangen-Hautklinik Studienambulanz ( Site 0905)

    Erlangen, Bavaria, 91054, Germany

  • UniversitätsSpital Zürich ( Site 1401)

    Zurich, Canton of Zurich, 8091, Switzerland

  • Universitätsklinikum Münster-Hautklinik ( Site 0904)

    Münster, North Rhine-Westphalia, 48149, Germany

  • Virginia Clinical Research, Inc. ( Site 0109)

    Norfolk, Virginia, 23502, United States

  • Westmead Hospital-Dermatology ( Site 1701)

    Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.